908 Devices Q2 revenue beats on increased VipIR sales - MASS News | Rallies
908 Devices Q2 revenue beats on increased VipIR sales M MASS • 2026-08-11 Outlook
908 Devices raises 2026 revenue outlook to $68 mln-$70 mln, up from $67 mln-$70 mln
Company expects 2026 revenue growth of 21% to 25% year-over-year
Company cites robust pipeline and recent orders supporting second-half revenue outlook
Overview
U.S. handheld chemical analysis tool maker's Q2 revenue grew 23%, beating analyst expectations
Net loss for Q2 widened, missing analyst estimates
Company raised low end of 2026 revenue outlook, now expects 21% to 25% growth
Result Drivers
VipIR product sales - Co said Q2 revenue growth was driven by increased sales of VipIR chemical identification devicesU.S. agency demand - Co said momentum with U.S. state and local customers remained strong, representing more than half of revenueChannel mix shift - Co attributed improved adjusted gross margin to higher product revenues and a shift in channel mix Key details and analyst coverage Q2 Revenue Beat $16.10 mln $15.37 mln (5 Analysts) Q2 Loss Per Share $0.32 Q2 Net Loss Miss $11.90 mln $6.32 mln (3 Analysts) Q2 Gross Profit $8.30 mln Q2 Operating Expenses $21.20 mln
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for 908 Devices Inc. is $11.00, about 25% above its August 10 closing price of $8.80
•
2026-08-11
MASS•
